Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2002-06-18
2003-07-01
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000, C424S493000, C424S497000, C424S484000, C424S486000, C424S488000, C424S422000, C424S423000, C424S426000
Reexamination Certificate
active
06586011
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates generally to methods of treatment and pharmaceutical compositions, and more particularly, but not by way of limitation, to delivery systems for pharmaceutical compositions.
SUMMARY OF THE INVENTION
According to the present invention, pharmaceutical compositions comprising a plurality of microcapsules suitable for parenteral injection into a mammal, as well as methods for preparing same, are provided. Broadly, the microcapsules comprise a plasminogen activator entrapped in a biocompatible, biodegradable, substantially water-soluble polymeric matrix.
The present invention relates to a method of treating a thrombotic condition in a mammal in need of such therapy, and such method includes parenterally injecting into the mammal a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is composed of a plurality of microcapsules, each microcapsule comprising a plasminogen activator entrapped in a biocompatible, biodegradable, substantially water-soluble polymeric matrix.
The present invention also relates to a method of reducing the time required for reperfusion of an artery containing a thrombus in a mammal as compared with the reperfusion time of an artery in a mammal administered an equal amount of a plasminogen activator in free form or an equal amount of a liposome-encapsulated plasminogen activator. Broadly, the method includes parenterally injecting into the mammal a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is composed of a plurality of microcapsules, each microcapsule comprising a plasminogen activator entrapped in a biocompatible, biodegradable, substantially water-soluble polymeric matrix.
An object of the present invention is to provide a pharmaceutical composition which provides rapid delivery of a plasminogen activator to an occluded blood vessel.
Another object of the present invention, while achieving the before-stated object, is to provide a process for preparing such pharmaceutical composition.
Another object of the present invention, while achieving the before-stated objects, is to provide a method for treatment of a thrombotic condition in a mammal comprising injecting into the mammal a therapeutically effective amount of such pharmaceutical composition.
Other objects, features and advantages of the present invention will become apparent from the following detailed description when read in conjunction with the accompanying drawings and appended claims.
REFERENCES:
patent: 5078994 (1992-01-01), Nair et al.
patent: 5470582 (1995-11-01), Supersaxo et al.
patent: 5503850 (1996-04-01), O'Rear, III et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 6051259 (2000-04-01), Johnson et al.
LiZL; Zhang NZ, Nie YH, Accelerated thrommbolysis by Liposomal-encapsulated urokinase in a canine model of acute myocardial infarcation National Library of Medicine: IGM Full Record Screen.
W.R. Perkins, D.E. Vaughan, S.R. Plavin, W.L. Daley, J. Rauch, L. Lee, A.S. Janoff, “Streptokinase Entrapment in Interdigitation-Fusion Liposomes Improves Thrombolysis in an Experimental Rabbit Model”, Thromb Hacmost, 1997, 77: 1174-8.
Phillip D. Nguyen, Edgar A. O'Rear, Arthur E. Johnson, Eugene Patterson, Thomas L. Whitsett and Remesh Bhakta, “Accelerated Thrombolysis and Reperfusion in a Canine Model of Myocardial Infarction by Liposomal Encapsulated of Streptokinase”, Circulation Research, Mar. 1990, vol. 66, No. 3, p. 875-878.
J.L. Heeremans, R. Prevost, M.E. Bekkers, P. Los, J.J. Emeis, C. Kluff and D.J. Crommelin, “Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) containing Liposomes in Rabbits: a Comparison with Free t-PA”, Thromb Haemost, Mar. 1995; 73(3); p. 488-494.
Smadar Cohen, Toshio Yoshioka, Melissa Lucarelli, Lena H. Hwang and Robert Langer, “Controlled Delivery Systems for Proteins Based on Poly (lactic/Glycolic Acid Microspheres”, Pharmaceutical Research, 1991, vol. 8, No. 6, p. 713-720.
P.D. Nguyen, E.A. O'Rear, A.E. Johnson, R. Lu and B.M. Fung, “Thrombolysis Using Liposomal-Encapsulated Streptokinase: An In Vitro Study (42995)”, P.S.E.B.M. 1989, vol. 192, p. 261-269.
Tiffany Medlin Osborn, M.D., Marian P. LaMonte, M.D., MSN, and Wade R. Gaasch, M.D., “Intravenous Thrombolytic Therapy for Stroke: A Review of Recent Studies and Controversies”, Annals of Emergency Medicine, Aug. 1999 34:2, p. 244-255.
Thomas G. Kwiatkowski, M.D., Richard B. Libman, M.D., Michael Frankel, M.D., Barbara C. Tilley, Ph.D., Lewis B. Morgenstern, M.D., Mei Lu, Ph.D., Joseph P. Broderick, M.D., Christopher A. Lewandowski, M.D., John R. Marler, M.D., Steven R. Levine, M.D., and Thomas Brott, M.D., “Effects of Tissue Plasminogen Activator For Acute Ischemic Stroke At One Year”, New England Journal of Medicine, Jun. 10, 1999, vol. 340, p. 1781-1787.
Jung-He Wu, Khalid Siddiqui and Scott L. Diamond, “Transport Phenomena and Clotdissolving Therapy: An Experimental Investigation of Diffusion-Controlled and Permeation-enhanced Fibrinolysis”, Thromb Haemost, Jul. 1994; 72 (1), p. 105-112.
T.R. Tice and D.R. Cowsar, “Biodegradable controlled-release parenteral systems”, Pharmaceutical Technology, Nov., 1964, vol. 8, Issue 11, p. 26-35.
Toyomi Sato, Motoko Kanke, Hans G. Schroeder and Patrick Deluca, “Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques”, Pharmaceutical Research, vol. 5, No. 1980, pp. 21-30.
Lee R. Beck, Ph.D., Donald R. Cowsar, Ph.D., Danny H. Lewis, Ph.D., Robert J. Cosgrove, Jr., Ph.D., Charles T. Riddle, B.S., Suzanne L. Lowry, B.S. and Thomas Epperly, B.S., “A New Long-Acting Injectable Microcapsule System For the Administration of Progesterone”, Fertility and Sterility, May 1979, vol. 31, No. 5, P. 545-551.
Jeffrey L. Cleland, “Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for therapeutics and Vaccines”, Biotechnol Prog., 1998, vol. 14, p. 102-107.
Jeffrey L. Cleland, “Protein Delivery from Biodegradable Microspheres”, in Protein Delivery: Physical Systems, Sanders and Hendren, eds., Plenum Press, New York, 1997, p. 1-43.
Leach Jonathan K.
O'Rear Edgar
Di Nola-Baron Liliana
Dunlap Codding & Rogers P.C.
Southpac Trust International Inc.
Spear James M.
LandOfFree
Microencapsulated plasminogen activators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microencapsulated plasminogen activators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated plasminogen activators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3088369